Conversation with Raphael Mechoulam.

  title={Conversation with Raphael Mechoulam.},
  author={R. Mechoulam},
  volume={102 6},
In this occasional series we record the views and personal experience of people who have specially contributed to the evolution of ideas in the Journal’s field of interest. Entering what was, at the start, a neglected field, Raphael Mechoulam went on to pursue, over the next 40 years, a highly productive career in cannabis research. This interview charts a sequence of discoveries and reveals something of the dedication and intellectual daring which has characterized the enterprise throughout. 

Topics from this paper

From Bud to Brain: A Psychiatrist's View of Marijuana
The trend toward liberalizing medical and recreational marijuana use is increasing the obligation on clinicians to provide useful information to the public. This book summarizes the science allExpand
Gastrointestinal Physiology
Curiosity and the quest for addressing human maladies or problems of nature are possibly the key driving forces for discoveries in science. Apart from shaping the reputation of the scientists andExpand
Cannabis Use , Effect And Potential Therapy For Alzheimer ' s , MS and Parkinson ' s
    — Cannabis (marijuana) is the most widely produced plant-based illicit drug worldwide and the illegal drug most frequently used in Europe. Its use increased in almost all EU countries during theExpand
    Cannabinoids, Chemical Senses, and Regulation of Feeding Behavior
    The CB1 receptor represents the most relevant target molecule of cannabinoid components on nervous system and whole-body energy homeostasis and can increase appetite and stimulate feeding, whereas blockade of CB1 suppresses hunger and induces hypophagia. Expand
    Endocannabinoids in Body Weight Control
    The overall goal is to address the molecular, cellular and pharmacological logic behind central and peripheral eCB-mediated body weight control, and to figure out how these precise mechanistic insights are currently transferred into the development of next generation cannabinoid medicines displaying clearly improved safety profiles, such as significantly reduced side effects. Expand
    Endocannabinoids, cannabinoid receptors and inflammatory stress: an interview with Dr. Pál Pacher
    • H. Rosenberg
    • Biology, Medicine
    • Journal of leukocyte biology
    • 2007
    The role of the cannabinoid receptor 2 (CB2) agonist, HU-308, in preventing tissue damage in an experimental model of tissue ischemia / reperfusion injury is explored. Expand
    PET Studies of Neurotransmission in Temporal Lobe Epilepsy
    PET Studies of Neurotransmission in Temporal Lobe Epilepsy
    Monumental Marijuana Discoveries
    Contemporary Routes of Cannabis Consumption
    • Julianne Moy
    • Medicine
    • The Journal of the American Osteopathic Association
    • 2019


    Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
    strongly solvated than triple ions,lb-5 the difference being greater for cations of smaller radii, leading to a trend to smaller K with decreasing cationic radii. Both effects, in oppositeExpand
    Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
    Upon intravenous administration to mice, 2-Ara-Gl caused the typical tetrad of effects produced by THC: antinociception, immobility, reduction of spontaneous activity, and lowering of the rectal temperature. Expand
    Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
    Four of the 8 CBD subjects remained almost free of convulsive crises throughout the experiment and 3 other patients demonstrated partial improvement in their clinical condition, while CBD was ineffective in 1 patient. Expand
    Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
    Arachidonylethanolamide, an arachidonic acid derivative in porcine brain, was identified in a screen for endogenous ligands for the cannabinoid receptor. The structure of this compound, which hasExpand
    The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.
    Data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA. Expand
    Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats
    CBD modulates waking via activation of neurons in the hypothalamus and DRD, both regions are apparently involved in the generation of alertness, and CBD increases DA levels as measured by microdialysis and HPLC procedures. Expand
    An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
    It is shown that, after injury to the mouse brain, 2-AG may have a neuroprotective role in which the cannabinoid system is involved and this effect was dose-dependently attenuated by SR-141761A, an antagonist of the CB1 cannabinoid receptor. Expand
    N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties
    • G. Milman, Y. Maor, +8 authors R. Mechoulam
    • Biology, Medicine
    • Proceedings of the National Academy of Sciences of the United States of America
    • 2006
    ARA-S may represent an endogenous agonist for this receptor and produces endothelium-dependent vasodilation of rat isolated mesenteric arteries and abdominal aorta and stimulates phosphorylation of p44/42 mitogen-activated protein (MAP) kinase and protein kinase B/Akt in cultured endothelial cells. Expand
    Determination and characterization of a cannabinoid receptor in rat brain.
    The criteria for a high affinity, stereoselective, pharmacologically distinct cannabinoid receptor in brain tissue have been fulfilled. Expand
    Hashish. I. The structure of cannabidiol.
    Cannabidiol, one of the major components of hashish, has been shown to possess structure IIIa. Expand